MarketCapExport financials
PTC Therapeutics (PTCT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
PTC Therapeutics Income Statement 2025-2010 | PTCT
Brief overview of financial performance at PTC Therapeutics
The overview follows changes across a five-year period. PTC Therapeutics reported revenue of $381 million in 2020 and $1.7 billion by 2025. Overall revenue changed by +354.5%, equal to an annualized rate of about 35.4%. Revenue growth reflects a pronounced phase of business expansion.
EBITDA changed from −$388 million to $906 million (+333.3%). Operating performance weakened relative to revenue. The EBITDA share of revenue changed from −102% to 52.3%. Higher profitability strengthens the quality of operating growth.
The net financial result changed from −438 million dollars to 683 million dollars. The business moved out of a loss and ended the period with a profit.
Market value was $3.8 billion at the start and $5.6 billion at the end. The financial trend was stronger than the market valuation.
What the figures show
Most key measures improved without a pronounced weak signal. The strongest signals are improving net profitability, a larger revenue base and an improving EBITDA margin. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement PTC Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
5.56 B | 3.93 B | 2.13 B | 3.25 B | 2.47 B | 3.77 B | 3.02 B | 1.39 B | 1.05 B | 415 M | 801 M | 1.73 B | 344 M | - | - | - |
Shares |
79.5 M | 76.8 M | 74.8 M | 71.7 M | 70.5 M | 66 M | 58.9 M | 46.6 M | 39.2 M | 34 M | 33.6 M | 31.6 M | 12.8 M | - | - | - |
Historical Prices |
69.9 | 51.1 | 28.4 | 45.3 | 35.1 | 57.1 | 54.8 | 34.5 | 25.8 | 13.6 | 7.98 | 71.3 | 31.4 | - | - | - |
Net Income |
683 M | -363 M | -627 M | -559 M | -524 M | -438 M | -252 M | -128 M | -79 M | -142 M | -170 M | -93.8 M | -51.6 M | -26.2 M | 30.9 M | - |
Revenue |
1.73 B | 807 M | 938 M | 699 M | 539 M | 381 M | 307 M | 265 M | 194 M | 82.7 M | 36.8 M | 23 M | 31.3 M | 28.8 M | 99 M | - |
Cost of Revenue |
- | - | - | - | - | - | 12.1 M | 12.7 M | 4.58 M | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | 295 M | 252 M | 190 M | - | 36.8 M | 25.2 M | 34.7 M | 33.9 M | - | - |
Operating Income |
867 M | -303 M | -440 M | -447 M | -374 M | -432 M | -241 M | -116 M | -64.3 M | -132 M | -167 M | -99.4 M | -45.4 M | -26.8 M | 30.6 M | - |
Interest Expense |
-18.1 M | 6.54 M | 10.1 M | -49.2 M | -57.9 M | 85.2 M | 13.7 M | 129 K | -1.28 M | -1.21 M | -465 K | -213 K | 38 K | 1.78 M | 461 K | - |
EBITDA |
906 M | -227 M | -203 M | -319 M | -310 M | -388 M | -165 M | -73.5 M | -48.9 M | -129 M | -164 M | -97.2 M | -43 M | -24.1 M | 33.5 M | - |
Operating Expenses |
864 M | 1.11 B | 1.38 B | 1.15 B | 913 M | 813 M | 488 M | 348 M | 254 M | 215 M | 204 M | 122 M | 76.7 M | 60.8 M | - | - |
General and Administrative Expenses |
347 M | 301 M | 333 M | 326 M | 286 M | 245 M | 203 M | 154 M | 121 M | 97.1 M | 82.1 M | 44.8 M | 25.2 M | 14.6 M | 16.2 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement PTC Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
83.5 M | 83 M | 82.5 M | 892 K | 78.5 M | 78.2 M | 78.1 M | 129 K | 76.9 M | 76.7 M | 76.5 M | 220 K | 75.4 M | 74.7 M | 73.7 M | 313 K | 71.7 M | 71.4 M | 71.2 M | -141 M | 70.6 M | 70.4 M | 70.2 M | 960 K | 67.6 M | 65.2 M | 62.4 M | 1.06 M | 56.5 M | 55.9 M | 55.9 M | 1.27 M | 48.1 M | 46.1 M | 41.6 M | 749 K | 41.3 M | 39.6 M | 34.3 M | 41.6 M | 34.1 M | 34 M | 33.9 M | 97.4 K | 33.9 M | 33.6 M | 33.1 M | 3.12 M | 29.4 M | 29.3 M | 24.5 M | 3.83 M | 23.8 M | 2.65 M | 4.53 K | 4.53 K | 4.54 K | 3.09 K | - | - | - | - | - |
Net Income |
-51.7 M | 83.5 M | -2.81 M | -135 M | 15.9 M | -64.8 M | 867 M | -65.9 M | -107 M | -99.2 M | -91.6 M | -156 M | -133 M | -199 M | -139 M | -171 M | -109 M | -152 M | -127 M | -143 M | -134 M | -118 M | -129 M | -74.4 M | -69.7 M | -181 M | -113 M | -77.7 M | -60 M | -41.8 M | -72.1 M | -48.3 M | -51 M | -9.52 M | -19.3 M | 1.27 M | -33.7 M | -17.5 M | -29.1 M | -26.8 M | -35.2 M | -38.9 M | -41.2 M | -50.9 M | -43.2 M | -38.4 M | -37.9 M | -27.3 M | -27.3 M | -25.1 M | -14.1 M | -17.9 M | -4.42 M | -14.6 M | -14.7 M | -6.27 M | -7.3 M | -6.07 M | -6.6 M | - | - | - | - |
Revenue |
358 M | 361 M | 273 M | 165 M | 211 M | 179 M | 1.18 B | 213 M | 197 M | 187 M | 210 M | 307 M | 197 M | 214 M | 220 M | 167 M | 217 M | 166 M | 149 M | 165 M | 139 M | 117 M | 118 M | 119 M | 118 M | 75.2 M | 68.3 M | 96.5 M | 71.4 M | 85.5 M | 53.6 M | 85.8 M | 53.6 M | 68.7 M | 56.1 M | 58 M | 41.8 M | 47.9 M | 26.4 M | - | 23 M | 15.6 M | 18.9 M | - | 9.78 M | 6.77 M | 7.48 M | - | 1.69 M | 1.68 M | 9.22 M | 4.41 M | 16.3 M | 6.85 M | 7.14 M | 6.64 M | 7.2 M | 7.59 M | 12.5 M | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.54 M | 3.01 M | 3.21 M | 2.38 M | 3.76 M | 3.29 M | 2.57 M | 3.04 M | 2.44 M | 1.58 M | 758 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 92.9 M | 68.4 M | 82.3 M | 51.2 M | 82.1 M | 50.3 M | 66.2 M | 53 M | 55.5 M | 40.2 M | 47.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
25.1 M | 149 M | 45 M | -71.3 M | 3.02 M | -35 M | 970 M | -162 M | -54.5 M | -40.2 M | -45.5 M | 5.82 M | -118 M | -210 M | -118 M | -200 M | -68.2 M | -92.4 M | -86.5 M | -84.7 M | -93.1 M | -98.5 M | -98.1 M | -96.4 M | -55.1 M | -187 M | -93 M | -72.8 M | -60.5 M | -38.8 M | -69.1 M | -45.1 M | -48.2 M | -5.57 M | -16.7 M | 5.45 M | -30.9 M | -12.5 M | -26.4 M | -25 M | -32.1 M | -36.6 M | -38.4 M | -48.2 M | -42.2 M | -38.6 M | -38.1 M | -32.2 M | -27.6 M | -25.4 M | -14.2 M | -18.1 M | -4.28 M | -14.5 M | -8.58 M | -6.03 M | -7.06 M | -7.5 M | -6.22 M | - | - | - | - |
Interest Expense |
-1.07 M | -2.95 M | 1.61 M | -12.5 M | 6.5 M | -5.74 M | -6.3 M | 8.85 M | -1.87 M | -2.02 M | 1.59 M | 19 M | -20.3 M | 1.48 M | 9.96 M | 35.1 M | -38.1 M | -34.4 M | -11.9 M | -31.4 M | -18.8 M | 3.17 M | -10.9 M | 58.9 M | 28.8 M | 11.3 M | -13.8 M | 11.2 M | 2.8 M | -183 K | -109 K | -937 K | 734 K | -673 K | 1 M | 94 K | 766 K | -1.82 M | -318 K | 686 K | -786 K | -387 K | -721 K | 42 K | -51 K | -88 K | -368 K | -138 K | -35 K | 17 K | -57 K | 41 K | -37 K | -19 K | 54 K | - | 5.51 K | 1.77 M | - | - | - | - | - |
EBITDA |
37.7 M | 161 M | 56.5 M | -62 M | 10.6 M | -30.9 M | 974 M | -159 M | -51.5 M | -37.4 M | 6.08 M | 83 M | -59.5 M | -162 M | -78.2 M | -165 M | -37.2 M | -66.1 M | -63 M | -68.4 M | -78.7 M | -85.7 M | -86.9 M | -85.8 M | -45.5 M | -179 M | -85 M | -64.8 M | -53.4 M | -32.2 M | -63.1 M | -39.1 M | -42.4 M | 19 K | -11.3 M | 10.9 M | -21.2 M | -11 M | -25.7 M | -25 M | -29.6 M | -35.7 M | -37.6 M | -50.3 M | -41.5 M | -37.9 M | -37.4 M | -31.7 M | -27.1 M | -24.8 M | -13.6 M | -17.5 M | -2.46 M | -13.2 M | -7.95 M | -6.03 M | -5.01 M | -6.12 M | -6.22 M | - | - | - | - |
Operating Expenses |
333 M | 212 M | 228 M | 236 M | 208 M | 214 M | 206 M | 376 M | 251 M | 227 M | 256 M | 301 M | 315 M | 423 M | 338 M | 368 M | 285 M | 258 M | 235 M | 250 M | 232 M | 215 M | 216 M | 215 M | 174 M | 263 M | 161 M | 169 M | 132 M | 124 M | 123 M | 131 M | 102 M | 74.3 M | 72.8 M | 72.6 M | 72.7 M | 60.5 M | 52.9 M | 50.2 M | 55 M | 52.2 M | 57.3 M | 60.9 M | 52 M | 45.4 M | 45.6 M | 44.9 M | 29.3 M | 27 M | 23.4 M | 22.5 M | 20.6 M | 21.3 M | 15.7 M | 12.7 M | 14.3 M | 15.1 M | 18.7 M | - | - | - | - |
General and Administrative Expenses |
80.1 M | 80.6 M | 86.2 M | 96.9 M | 84 M | 85.3 M | 81 M | 84.7 M | 73.5 M | 69.5 M | 73.3 M | 76.3 M | 80.9 M | 88.4 M | 86.9 M | 92.7 M | 80.1 M | 79.9 M | 73.3 M | 86.5 M | 69.3 M | 68.9 M | 61.1 M | 75.5 M | 57.8 M | 53.7 M | 58.2 M | 63.5 M | 49.3 M | 49.2 M | 40.5 M | 48.7 M | 38.4 M | 33.5 M | 33 M | 35.5 M | 31.4 M | 28.9 M | 25.5 M | 24.2 M | 23.7 M | 23.4 M | 25.9 M | 25.9 M | 21.4 M | 17.2 M | 17.6 M | 18 M | 10.5 M | 8.73 M | 7.54 M | 7.48 M | 6.68 M | 6.6 M | 4.46 M | - | 3.78 M | 3.16 M | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company PTC Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Niderland
Israel
Schweiz
Australia
Britain
